Who are KW-2246's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Anti-OX40 Antibody PF-04518600, PF-05280586, GSK1325760A, KN057, MK-3415A, CM326.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/kw-2246.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

KW-2246 — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

KW-2246 (KW-2246) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: OX40 agonist monoclonal antibody. Area: Oncology.

phase 3 OX40 agonist monoclonal antibody OX40 Oncology Small molecule Live · refreshed every 30 min

Target snapshot

KW-2246 (KW-2246) — Kyowa Kirin Co., Ltd.. KW-2246 is a humanized monoclonal antibody that binds to and inhibits OX40, a co-stimulatory immune checkpoint receptor, to enhance T-cell activation and anti-tumor immunity.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
KW-2246 TARGET	KW-2246	Kyowa Kirin Co., Ltd.	phase 3	OX40 agonist monoclonal antibody	OX40
Anti-OX40 Antibody PF-04518600	anti-ox40-antibody-pf-04518600	Pfizer	marketed	Monoclonal antibody	OX40 receptor
PF-05280586	PF-05280586	Pfizer	phase 3	OX40 agonist monoclonal antibody	OX40
GSK1325760A	GSK1325760A	GlaxoSmithKline	phase 3	OX40 agonist monoclonal antibody	OX40 (TNFRSF4)
KN057	KN057	Suzhou Alphamab Co., Ltd.	phase 3	OX40 agonist monoclonal antibody	OX40
MK-3415A	MK-3415A	Merck Sharp & Dohme LLC	phase 3	OX40 agonist monoclonal antibody	OX40
CM326	CM326	Keymed Biosciences Co.Ltd	phase 3	OX40 agonist monoclonal antibody	OX40 (CD134)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (OX40 agonist monoclonal antibody class)

GlaxoSmithKline · 1 drug in this class
Keymed Biosciences Co.Ltd · 1 drug in this class
Kyowa Kirin Co., Ltd. · 1 drug in this class
Merck Sharp & Dohme LLC · 1 drug in this class
Pfizer · 1 drug in this class
Suzhou Alphamab Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). KW-2246 — Competitive Intelligence Brief. https://druglandscape.com/ci/kw-2246. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing